Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 6, 2002

View Archived Issues

Pliva and GSK extend macrolide antibiotics collaboration agreement

Eplerenone for the long-term treatment of chronic heart failure

UCB-34714: a new levetiracetam analogue discovered at UCB

Galapagos Genomics broadens functional genomics collaboration with P&G

CIMA advances OraVescent fentanyl into clinical trials

Hexvix demonstrates benefit in detection of bladder cancer

Lexicon Genetics initiates small molecule discovery in obesity

Phase I/II results for HuMax-IL-15 in RA

Paratek receives SBIR grant for antimalarial tetracyclines

Solvay identifies potent, selective, orally active CB1 antagonist, initially targeted for psychosis

Novel 5-HT2A/2C and H1 antagonist from Janssen with anxiolytic-like activity

Clinical development candidate for anxiety selected at Janssen

Inhibitors of phosphopantetheine adenylyltransferase as potential antibacterial agents

New class of PTP1B inhibitors discovered at Morphochem

SDZ-LAV-694: a topical antiproliferative agent with a favorable pharmacological profile

Phase II clinical results in psoriasis announced for IDEC-114

SGN-30 safe and associated with antitumor activity in phase I trial

ACAM-1000 smallpox vaccine completes phase I trial

CX-516 enters testing for fragile X syndrome

Actimmune shows survival benefit in phase III IPF trial

Eloxatin now available for second-line treatment of colorectal cancer

Enrollment completed in phase II study of EGF cancer vaccine

Prodrugs of excitatory amino acids prepared at Lilly

New agents for diabetes and hyperlipidemia designed by Takeda scientists

Orally bioavailable and safe SGLT2 inhibitors useful for diabetes and related disorders

Tachykinin antagonists and potential uses described in recent patent

Compounds that upregulate LDL receptor expression disclosed in patent literature